Medline Industries (Nasdaq: MDLN) reported Q3 2026 adjusted earnings of $0.44 per share on November 4, against a consensus estimate of $0.32. Revenue came in at $7.9 billion, up 10.4% year over year. Adjusted EBITDA reached $1.0 billion for the quarter, up 11.8%. The company raised its full-year organic sales growth guidance to 10.0% to 10.5% from a prior range of 9.0% to 10.0%, and announced a $1 billion share repurchase program the same day. The stock jumped more than 10%.
Why This Stock Now
None of that is the real story. Medline became a public company in December 2025, completing its IPO on December 18, 2025, at $29 per share. It raised more than $7 billion in gross proceeds, and it was widely billed at the time as the largest healthcare IPO in history and the largest IPO of 2025. It began trading on Nasdaq on December 17, 2025. Since then, every quarter has beaten expectations, full-year guidance has moved higher, and the company just authorized its first buyback. Yet the stock sits near $40, below its first-day close. The gap between consistent execution and muted price appreciation points directly at one thing: about $12.6 billion of long-term debt.
The Business
Medline describes itself as the largest provider of medical-surgical products and supply chain solutions serving all points of care. It offers approximately 335,000 products globally, covering wound care, medical devices, home healthcare, and hospital supplies. That manufacturing footprint is the competitive moat. It makes switching providers expensive and slow for hospital systems that have integrated Medline’s supply chain tools and analytics. Nine-month net sales reached $22.9 billion, putting the company on pace for roughly $30 billion in annual revenue.
Why Wall Street Is Paying Attention
Sector rotation is working in Medline’s favor. Healthcare has been one of the two leading S&P 500 sectors in recent weeks, as capital rotates away from technology and toward earnings visibility. Medline’s business is about as defensively positioned as a company this size can be: hospitals buy surgical supplies regardless of interest rates or election outcomes. The buyback announcement adds a capital return layer to a stock that was previously priced only on debt reduction. Nine-month adjusted EBITDA of $2.8 billion, up 5.0% year over year, confirms the cash engine is running.
What’s Driving the Opportunity
The deleveraging math is what investors should track. The company used IPO proceeds to cut debt from roughly $16.4 billion at year-end 2024 to about $12.6 billion as of September 26, 2026. Management has targeted a net debt-to-EBITDA ratio below 3.0. With full-year adjusted EBITDA guided at $3.3 billion to $3.4 billion, reaching that leverage target requires several billion dollars of additional net debt reduction. Each step down expands the equity cushion and reduces interest expense, which currently consumes a substantial portion of operating income. The revenue beats help but the deleveraging timeline controls the valuation ceiling.
Morningstar analysts note that revenue growth and EBITDA growth are running above consensus, and the buyback signals management’s confidence that cash generation is durable enough to return capital while still paying down debt.
What Could Go Wrong
At roughly 80 times normalized earnings, the valuation relative to comparable distributors Cardinal Health and McKesson is striking. Those peers trade below 25 times. Medline’s P/E premium reflects the growth rate and market position, but it also compresses the margin of safety. Any disruption to the supply chain, tariff pressure on manufactured goods, or revenue deceleration that slows debt paydown could reset investor expectations quickly. Net income fell 1.2% in Q3 and declined 28.8% through nine months, mostly due to interest expense and IPO-related costs. Bottom-line improvement requires the balance sheet work to show up in earnings, and that takes time.
The Bottom Line
Medline is executing. Three consecutive quarters of double-digit revenue growth, a consistent earnings beat, raised guidance, and now a buyback add up to a management team doing what it said it would do after the IPO. The stock’s performance since listing reflects not a failing business but an investor base still pricing the debt before the equity. If Medline keeps deleveraging at the current pace while sustaining 10% revenue growth, the multiple compression that debt creates eventually reverses. That is the investment case, and it is not built on hope.
